These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 38962014)

  • 1. Universal CAR 2.0 to overcome current limitations in CAR therapy.
    Schlegel LS; Werbrouck C; Boettcher M; Schlegel P
    Front Immunol; 2024; 15():1383894. PubMed ID: 38962014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of dual-targeted CAR T-cell therapy].
    Kato I
    Rinsho Ketsueki; 2024; 65(7):662-667. PubMed ID: 39098017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
    Khvorost D; Kendall B; Jazirehi AR
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.
    Hallaj S; Meshkini F; Chaleshtari MG; Ghorbani A; Namdar A; Soleimanpour H; Jadidi-Niaragh F
    Cell Immunol; 2019 Nov; 345():103963. PubMed ID: 31445668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology.
    Mishra HK; Kalyuzhny A
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
    Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
    Mol Ther; 2024 Aug; 32(8):2444-2460. PubMed ID: 38822527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
    Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.